Mauna Kea Technologies SA (0P5I.L)
| Previous close | 0.4175 |
| Open | 0.4180 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.4180 - 0.4180 |
| 52-week range | 0.4140 - 0.7825 |
| Volume | |
| Avg. volume | 87 |
| Market cap | 128,313 |
| Beta (5Y monthly) | 1.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3530 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireMauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
PARIS, December 05, 2023--Regulatory News: Mauna Kea Technologies (Paris:ALMKT):
Business WireMauna Kea Technologies and Telix Pharmaceuticals to Expand Partnership in Uro-oncologic Surgery
MELBOURNE, Australia & PARIS, November 13, 2023--Regulatory News: Telix Pharmaceuticals Limited (ASX: TLX, Telix) and Mauna Kea Technologies (Euronext Growth: ALMKT, Mauna Kea), today announced an expansion of the IRiS (Imaging and Robotics in Surgery) Alliance through a strategic €6 million investment of Telix in Mauna Kea Technologies to develop new hybrid pharmaceutical-device products through the combination of Telix’s cancer-targeting agents with Mauna Kea’s Cellvizio® surgical endomicrosco
Business WireMauna Kea Technologies Announces First Patient Enrolled in the Pivotal CLEVER Clinical Trial in Peripheral Lung Cancer
PARIS & BOSTON, November 02, 2023--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the first patient enrollment in the multi-center randomized controlled trial (RCT) entitled "Confocal Laser Endomicroscopy VERification" (CLEVER, NCT06079970)1 in collaboration with the Amsterdam University Medical Centers (UMC) for the diagnosis and management of
